Biguanides and sulfonylureas are by far the most heavily prescribed type 2 diabetes (T2D) drug classes. However, several branded agents are jostling for position as second-line treatment options, including the DPP-IV inhibitors Januvia and Tradjenta, the SGLT-2 inhibitors Jardiance, Invokana, and Farxiga, the GLP-1 receptor agonists Victoza and Trulicity, and the insulins. Optimized drug treatment can improve glycemic control, which can decrease the risk of specific comorbid conditions in T2D, including vascular and hepatic sequelae. In an increasingly competitive and congested market, brand differentiation and understanding of patient characteristics are ever more critical for marketers.
Patient Profiler provides disease-specific, patient-level analysis of the key demographic, clinical, and cost-based metrics underlying brand use, all sourced using DRG’s comprehensive real-world data repository.
Type 2 Diabetes Patient Profiler sources demographic, clinical, and cost-based metrics using DRG’s real-world data repository.
Boehringer Ingelheim, Janssen, Eli Lilly, Merck & Co., Novo Nordisk, and Sanofi.
Biguanides, Humalog, Invokana, Januvia, Jardiance, Lantus, Levemir, NovoLog, premixed insulin, sulfonylureas, Tradjenta, Toujeo, Trulicity, and Victoza.